US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 127.490
  • +8.260+6.93%
Trading Aug 8 15:10 ET
568.11BMarket Cap43.38P/E (TTM)

Novo-Nordisk A/S Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Novo-Nordisk A/S Earnings Date

Currency: DKK

Period

Q2 2024 Earnings

Aug 7, 2024

Revenue(YoY)

68.06B

+25.34%
EPS(YoY)

4.49

+3.94%
Analyst Rating

Strong Buy

Aug 8, 2024

Novo-Nordisk A/S Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 10 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: DKK

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 82.156B--
--2024/Q3-- / 73.575B--
Aug 7, 20242024/Q268.060B / 68.563B--
May 2, 20242024/Q165.349B / 63.573B--
Jan 31, 20242023/Q465.863B / 61.207B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 82.156B--
--2024/Q3-- / 73.575B--
Aug 7, 20242024/Q268.060B / 68.563B--
May 2, 20242024/Q165.349B / 63.573B--
Jan 31, 20242023/Q465.863B / 61.207B
Novo Nordisk Q4 2023 earnings conference call
Jan 31 06:00
Replay

Unlock Free Earnings Estimates

Novo-Nordisk A/S Earnings Reports

  • 6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

    Aug 7 06:56 ET

  • 6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

    Jun 26 13:22 ET

  • 6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

    May 2 07:18 ET

  • Novo-Nordisk A/S | 6-K: Report of foreign private issuer (related to financial reporting)

    Jan 31 07:03 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Aug 8, 2024

    Strong Buy

    • Buy

      87.50%

    • Hold

      0.00%

    • Sell

      12.50%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg
    Concept Weight Loss Drugs
    Weight Loss Drugs
    Intraday+7.16%